<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the response to treatment of autoinflammatory diseases from an international registry and an up-to-date literature review </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The response to treatment was studied in a web-based registry in which clinical information on anonymised patients with autoinflammatory diseases was collected retrospectively as part of the Eurofever initiative </plain></SENT>
<SENT sid="2" pm="."><plain>Participating hospitals included paediatric rheumatology centres of the Paediatric Rheumatology International Trial Organisation network and adult centres with a specific interest in autoinflammatory diseases </plain></SENT>
<SENT sid="3" pm="."><plain>The following diseases were included: familial Mediterranean <z:hpo ids='HP_0001945'>fever</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e>), cryopyrin-associated <z:e sem="disease" ids="C0585274" disease_type="Disease or Syndrome" abbrv="">periodic syndromes</z:e> (CAPS), <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF)-receptor associated <z:e sem="disease" ids="C0585274" disease_type="Disease or Syndrome" abbrv="">periodic syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TRAPS</z:e>), <z:chebi fb="0" ids="25350">mevalonate</z:chebi> kinase deficiency (MKD), pyogenic <z:hpo ids='HP_0001369'>arthritis</z:hpo> pustulosis <z:hpo ids='HP_0001061'>acne</z:hpo> (PAPA) syndrome, deficiency of interleukin-1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> (DIRA), NLRP12-related periodic <z:hpo ids='HP_0001945'>fever</z:hpo> and periodic <z:hpo ids='HP_0001945'>fever</z:hpo> <z:e sem="disease" ids="C0016514" disease_type="Disease or Syndrome" abbrv="">aphthosis</z:e> <z:e sem="disease" ids="C0031350" disease_type="Disease or Syndrome" abbrv="">pharyngitis</z:e> <z:e sem="disease" ids="C0001416,C0024205" disease_type="Disease or Syndrome;Sign or Symptom" abbrv="">adenitis</z:e> (PFAPA) syndrome </plain></SENT>
<SENT sid="4" pm="."><plain>Cases were independently validated by experts for each disease </plain></SENT>
<SENT sid="5" pm="."><plain>A literature search regarding treatment of the abovementioned diseases was also performed using Medline and Embase </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: 22 months from the beginning of the enrolment, complete information on 496 validated patients was available </plain></SENT>
<SENT sid="7" pm="."><plain>Data from the registry in combination with evidence from the literature confirmed that <z:chebi fb="0" ids="23359">colchicine</z:chebi> is the treatment of choice for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e> and IL-1 blockade for DIRA and CAPS </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="50858">Corticosteroids</z:chebi> on demand probably represent a valid therapeutic strategy for PFAPA, but also for MKD and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TRAPS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with poorly controlled MKD, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TRAPS</z:e>, PAPA or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e> may benefit from IL-1 blockade; anti-TNF treatment may represent a possible valuable alternative </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In the absence of high-grade evidence, these results could serve as a basis for therapeutic guidelines and to identify candidate drugs for future therapeutic trials </plain></SENT>
</text></document>